5 years later, CAR-T pioneer Kymriah offers jaw-dropping evidence of durable remissions — even as it still proves a tough sell
Just a couple of weeks after Bristol Myers Squibb finally won an FDA OK for liso-cel, investigators at Penn posted a 5-year update on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
